AngioDynamics (NASDAQ:ANGO) Posts Earnings Results, Beats Estimates By $0.02 EPS

AngioDynamics (NASDAQ:ANGO) announced its quarterly earnings data on Thursday. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02, Zacks reports. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The company had revenue of $75.71 million for the quarter, compared to the consensus estimate of $72.69 million. During the same period in the previous year, the business earned ($0.11) EPS. The firm’s revenue was up 12.1% compared to the same quarter last year. AngioDynamics updated its FY 2026 guidance to -0.330–0.230 EPS.

AngioDynamics Stock Down 0.9%

Shares of ANGO stock opened at $11.64 on Friday. The stock has a market cap of $478.17 million, a price-to-earnings ratio of -14.92 and a beta of 0.78. The business’s fifty day moving average is $9.94 and its 200 day moving average is $9.76. AngioDynamics has a twelve month low of $5.83 and a twelve month high of $13.50.

Institutional Investors Weigh In On AngioDynamics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its holdings in AngioDynamics by 9.6% in the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock worth $2,434,000 after acquiring an additional 22,658 shares in the last quarter. Invesco Ltd. boosted its holdings in AngioDynamics by 2.2% in the second quarter. Invesco Ltd. now owns 122,596 shares of the medical instruments supplier’s stock worth $1,216,000 after acquiring an additional 2,667 shares in the last quarter. American Century Companies Inc. boosted its holdings in AngioDynamics by 15.8% in the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock worth $960,000 after acquiring an additional 13,217 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in AngioDynamics by 28.3% in the second quarter. Squarepoint Ops LLC now owns 85,696 shares of the medical instruments supplier’s stock worth $850,000 after acquiring an additional 18,879 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in AngioDynamics by 46.0% in the second quarter. Jane Street Group LLC now owns 68,329 shares of the medical instruments supplier’s stock worth $678,000 after acquiring an additional 21,526 shares in the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on ANGO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Saturday, September 27th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of AngioDynamics in a research note on Wednesday, July 16th. Wall Street Zen lowered AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday. Lake Street Capital started coverage on AngioDynamics in a research note on Wednesday, July 16th. They issued a “buy” rating and a $24.00 target price for the company. Finally, Canaccord Genuity Group boosted their target price on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Friday. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, AngioDynamics has an average rating of “Moderate Buy” and an average price target of $19.33.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.